Q&A: Amid an M&A flurry at Charles River, longtime exec Birgit Girshick discusses how Covid-19 has changed the game

Josh Sullivan

Contract research and manufacturing has been running at a rapid clip amid the pandemic, and big players in the space have looked to leverage runaway …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Q&A: Amid an M&A flurry at Charles River, longtime exec Birgit Girshick discusses how Covid-19 has changed the game

Josh Sullivan

Sign up to read this article for free.

AbbVie makes another small I&I acquisition, buying Nimble for $200M

Gilead names Dietmar Berger CMO as it eyes R&D reset

Xaira hires former Roche exec as CMO; 'Tis the season for retirements at Alnylam, Regeneron

Editas to cut 65% of workforce, officially stops work on ex vivo sickle cell therapy

Boundless shares dip as it nixes cancer asset, reshuffles execs

The key to faster, more impactful research? Put patients in the driver’s seat

Q&A: Amid an M&A flur­ry at Charles Riv­er, long­time ex­ec Bir­git Gir­shick dis­cuss­es how Covid-19 has changed the game

Josh Sullivan

Sign up to read this article for free.

Ab­b­Vie makes an­oth­er small I&I ac­qui­si­tion, buy­ing Nim­ble for $200M

Gilead names Di­et­mar Berg­er CMO as it eyes R&D re­set

Xaira hires for­mer Roche ex­ec as CMO; 'Tis the sea­son for re­tire­ments at Al­ny­lam, Re­gen­eron

Ed­i­tas to cut 65% of work­force, of­fi­cial­ly stops work on ex vi­vo sick­le cell ther­a­py

Bound­less shares dip as it nix­es can­cer as­set, reshuf­fles ex­ecs

The key to faster, more im­pact­ful re­search? Put pa­tients in the dri­ver’s seat

Q&A: Amid an M&A flurry at Charles River, longtime exec Birgit Girshick discusses how Covid-19 has changed the game

AbbVie makes another small I&I acquisition, buying Nimble for $200M

Gilead names Dietmar Berger CMO as it eyes R&D reset

Xaira hires former Roche exec as CMO; 'Tis the season for retirements at Alnylam, Regeneron

Editas to cut 65% of workforce, officially stops work on ex vivo sickle cell therapy

Boundless shares dip as it nixes cancer asset, reshuffles execs

The key to faster, more impactful research? Put patients in the driver’s seat